{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"selank-tirzepatide","title":"Selank and Tirzepatide: Layered Evidence on Neurochemistry and Metabolic Pathways","body":"## What's breaking down\n\nNo single clinical condition is defined by the slug, so the layers come from the two compounds themselves. Tirzepatide targets metabolic load through GLP-1 and GIP receptor agonism, which produces weight loss but can coincide with reported psychiatric adverse events including anxiety in post-marketing data. Selank targets anxiety and neurochemistry pathways. When these two are considered together, the potential overlap is in the neurochemical stress layer that can accompany metabolic shifts.\n\n## Why Selank might help you\n\n1. **What keeps failing:** Chronic stress chemistry, non-restorative arousal states, or anxiety-like symptoms that may appear alongside metabolic therapies.\n2. **What Selank is studied to do:** Human trials in Russia examined Selank in patients with generalized anxiety disorder and neurasthenia; it showed anxiolytic effects comparable to low-dose benzodiazepines without sedation, cognitive impairment, or dependence.\n3. **Therefore for you:** If the anxiety or neurochemistry layer is part of your experience while using tirzepatide, Selank is discussed in the literature because it targets repair of that specific layer rather than broad suppression.\n\n## Why Tirzepatide might help you\n\n1. **What keeps failing:** Excess body weight creates mechanical and metabolic load on multiple systems.\n2. **What Tirzepatide is studied to do:** Large human trials demonstrate substantial weight reduction via dual GLP-1/GIP agonism.\n3. **Therefore for you:** If metabolic load contributes to overall strain, tirzepatide is discussed because it addresses that layer through documented weight-loss mechanisms.\n\n## How these fit together\n\nEach compound targets a different degeneration layer. Selank addresses anxiety and neurochemistry repair. Tirzepatide addresses metabolic load and body-weight reduction. The stack maps separate pathways without repetition.\n\n## What the evidence actually shows\n\nHuman data for Selank consists of small Russian trials (n=30–70) comparing it to medazepam or phenazepam in generalized anxiety disorder; anxiolytic scores improved similarly but without typical benzodiazepine side effects (Zozulia 2008, Filatova 2017). These are the only published human efficacy studies; no large Western RCTs exist. Preclinical work shows Selank modulates GABA-A receptor subunits and cytokine expression.\n\nFor tirzepatide, SURMOUNT and SURPASS trials report robust weight loss and glycemic control in thousands of participants. FAERS analysis of GLP-1 agonists including tirzepatide found psychiatric adverse event reports at ~1.18% of total reports, with anxiety comprising 38.7% of those psychiatric events (Tobaiqy 2024). Case reports describe possible mood improvement in two patients (Psychiatrist.com 2025). No human trials examine Selank plus tirzepatide.\n\n## What scientists say\n\nRussian researchers conclude Selank produces anxiolytic effects comparable to classical benzodiazepines without sedation or dependence (PMC articles 4757669, 5322660). Western reviews note limited sample sizes and lack of independent replication. Tirzepatide researchers focus on metabolic endpoints; psychiatric signals are monitored through pharmacovigilance rather than dedicated neurochemistry trials.\n\n## What people say on Reddit\n\nA single thread in r/Nootropics describes one user combining Selank with semaglutide and reporting improved mood and reduced social anxiety. Broader tirzepatide discussions mention variable mood or anxiety-like sensations tied to GI effects or glucose shifts, with some users switching agents for better tolerability.\n\n## What people say on X\n\nPosts list both compounds among popular research peptides but contain no detailed user experiences of the combination. Mentions are primarily catalog-style references to cognitive or metabolic categories.\n\n## What we do not know\n\nNo direct interaction data, long-term human safety data for the pair, or controlled trials exist. Mechanisms by which tirzepatide might influence anxiety pathways remain speculative. Selank’s Western evidence base is small and untranslated in full.\n\n## Safety and limits\n\nSelank is approved in Russia but not elsewhere; human safety data are limited to weeks-to-months durations in small cohorts. Tirzepatide carries known GI and rare psychiatric reporting signals. Any combined use lacks regulatory evaluation. All statements are for informational purposes only.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/selank-tirzepatide/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"Small Russian human trials (n=30-70) showed Selank anxiolytic effects comparable to benzodiazepines without sedation or dependence in GAD patients.","section":"What the evidence actually shows","tier":"human","source_ids":["s1","s4"],"source_status":"sourced","why_material":"Establishes the only published human efficacy data for Selank.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:34:01.341Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"FAERS analysis found psychiatric adverse events in ~1.18% of GLP-1 agonist reports; anxiety was 38.7% of those events across semaglutide, liraglutide, and tirzepatide.","section":"What the evidence actually shows","tier":"human","source_ids":["s9"],"source_status":"sourced","why_material":"Quantifies real-world psychiatric signal for tirzepatide context.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:34:01.341Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"No human trials or published data examine Selank combined with tirzepatide.","section":"What we do not know","tier":"mechanistic","source_ids":[],"source_status":"unsourced","why_material":"Clarifies absence of direct evidence for the cross.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:34:01.341Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/18454096/","title":"Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank in the therapy of generalized anxiety disorders and neurasthenia","quote":"The increase of this parameter and stronger positive correlations with anxiety level were observed during the treatment with selank mostly in patients with GAD.","summary":"2008 Russian trial comparing Selank to medazepam in 62 GAD/neurasthenia patients.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:34:01.031Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"cf562137a860145e269aef72e8fef75cb6747cdb838abb96347254023a6931cf"},{"id":"s4","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5322660/","title":"Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety","quote":"Clinical studies have shown that the anxiolytic effect of Selank is comparable to the effect of low doses of the benzodiazepine tranquilizers","summary":"Reviews Selank clinical data versus benzodiazepines.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:34:01.031Z","link_status":"ok","quote_status":"verified","prev":"cf562137a860145e269aef72e8fef75cb6747cdb838abb96347254023a6931cf","hash":"1964c13fb8d7e87aed0d132f2f618aca127797616f859affff4ca82faac48115"},{"id":"s9","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10960895/","title":"Psychiatric adverse events associated with semaglutide, tirzepatide and liraglutide","quote":"Depression was the most commonly reported adverse event (n = 187; 50.3%), followed by anxiety (n = 144; 38.7%)","summary":"FAERS pharmacovigilance analysis of psychiatric reports for GLP-1 agonists.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:34:01.031Z","link_status":"ok","quote_status":"verified","prev":"1964c13fb8d7e87aed0d132f2f618aca127797616f859affff4ca82faac48115","hash":"31acc61b3b171b7d33edbc80a35828b3b8c7cada0ead6b21edc370582f7e4f60"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-30T00:34:01.708Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"Selank and Tirzepatide: Layered Evidence on Neurochemistry and Metabolic Pathways","register":"source_ledger","body":"## What's breaking down\n\nNo single clinical condition is defined by the slug, so the layers come from the two compounds themselves. Tirzepatide targets metabolic load through GLP-1 and GIP receptor agonism, which produces weight loss but can coincide with reported psychiatric adverse events including anxiety in post-marketing data. Selank targets anxiety and neurochemistry pathways. When these two are considered together, the potential overlap is in the neurochemical stress layer that can accompany metabolic shifts.\n\n## Why Selank might help you\n\n1. **What keeps failing:** Chronic stress chemistry, non-restorative arousal states, or anxiety-like symptoms that may appear alongside metabolic therapies.\n2. **What Selank is studied to do:** Human trials in Russia examined Selank in patients with generalized anxiety disorder and neurasthenia; it showed anxiolytic effects comparable to low-dose benzodiazepines without sedation, cognitive impairment, or dependence.\n3. **Therefore for you:** If the anxiety or neurochemistry layer is part of your experience while using tirzepatide, Selank is discussed in the literature because it targets repair of that specific layer rather than broad suppression.\n\n## Why Tirzepatide might help you\n\n1. **What keeps failing:** Excess body weight creates mechanical and metabolic load on multiple systems.\n2. **What Tirzepatide is studied to do:** Large human trials demonstrate substantial weight reduction via dual GLP-1/GIP agonism.\n3. **Therefore for you:** If metabolic load contributes to overall strain, tirzepatide is discussed because it addresses that layer through documented weight-loss mechanisms.\n\n## How these fit together\n\nEach compound targets a different degeneration layer. Selank addresses anxiety and neurochemistry repair. Tirzepatide addresses metabolic load and body-weight reduction. The stack maps separate pathways without repetition.\n\n## What the evidence actually shows\n\nHuman data for Selank consists of small Russian trials (n=30–70) comparing it to medazepam or phenazepam in generalized anxiety disorder; anxiolytic scores improved similarly but without typical benzodiazepine side effects (Zozulia 2008, Filatova 2017). These are the only published human efficacy studies; no large Western RCTs exist. Preclinical work shows Selank modulates GABA-A receptor subunits and cytokine expression.\n\nFor tirzepatide, SURMOUNT and SURPASS trials report robust weight loss and glycemic control in thousands of participants. FAERS analysis of GLP-1 agonists including tirzepatide found psychiatric adverse event reports at ~1.18% of total reports, with anxiety comprising 38.7% of those psychiatric events (Tobaiqy 2024). Case reports describe possible mood improvement in two patients (Psychiatrist.com 2025). No human trials examine Selank plus tirzepatide.\n\n## What scientists say\n\nRussian researchers conclude Selank produces anxiolytic effects comparable to classical benzodiazepines without sedation or dependence (PMC articles 4757669, 5322660). Western reviews note limited sample sizes and lack of independent replication. Tirzepatide researchers focus on metabolic endpoints; psychiatric signals are monitored through pharmacovigilance rather than dedicated neurochemistry trials.\n\n## What people say on Reddit\n\nA single thread in r/Nootropics describes one user combining Selank with semaglutide and reporting improved mood and reduced social anxiety. Broader tirzepatide discussions mention variable mood or anxiety-like sensations tied to GI effects or glucose shifts, with some users switching agents for better tolerability.\n\n## What people say on X\n\nPosts list both compounds among popular research peptides but contain no detailed user experiences of the combination. Mentions are primarily catalog-style references to cognitive or metabolic categories.\n\n## What we do not know\n\nNo direct interaction data, long-term human safety data for the pair, or controlled trials exist. Mechanisms by which tirzepatide might influence anxiety pathways remain speculative. Selank’s Western evidence base is small and untranslated in full.\n\n## Safety and limits\n\nSelank is approved in Russia but not elsewhere; human safety data are limited to weeks-to-months durations in small cohorts. Tirzepatide carries known GI and rare psychiatric reporting signals. Any combined use lacks regulatory evaluation. All statements are for informational purposes only.","claims":[{"id":"c1","text":"Small Russian human trials (n=30-70) showed Selank anxiolytic effects comparable to benzodiazepines without sedation or dependence in GAD patients.","section":"What the evidence actually shows","tier":"human","source_ids":["s1","s4"],"source_status":"sourced","why_material":"Establishes the only published human efficacy data for Selank.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:34:01.341Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"FAERS analysis found psychiatric adverse events in ~1.18% of GLP-1 agonist reports; anxiety was 38.7% of those events across semaglutide, liraglutide, and tirzepatide.","section":"What the evidence actually shows","tier":"human","source_ids":["s9"],"source_status":"sourced","why_material":"Quantifies real-world psychiatric signal for tirzepatide context.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:34:01.341Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"No human trials or published data examine Selank combined with tirzepatide.","section":"What we do not know","tier":"mechanistic","source_ids":[],"source_status":"unsourced","why_material":"Clarifies absence of direct evidence for the cross.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:34:01.341Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/18454096/","title":"Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank in the therapy of generalized anxiety disorders and neurasthenia","quote":"The increase of this parameter and stronger positive correlations with anxiety level were observed during the treatment with selank mostly in patients with GAD.","link_status":"ok","quote_status":"verified"},{"id":"s4","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5322660/","title":"Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety","quote":"Clinical studies have shown that the anxiolytic effect of Selank is comparable to the effect of low doses of the benzodiazepine tranquilizers","link_status":"ok","quote_status":"verified"},{"id":"s9","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10960895/","title":"Psychiatric adverse events associated with semaglutide, tirzepatide and liraglutide","quote":"Depression was the most commonly reported adverse event (n = 187; 50.3%), followed by anxiety (n = 144; 38.7%)","link_status":"ok","quote_status":"verified"}]},"rationale":"","tokens_in":13828,"tokens_out":2557,"cost":0.0236775,"prev_hash":"genesis","hash":"de42a6219b5b21a1cae4ea8286f8c9c82b5fbdcc80db896c94c7d9449150e501"}],"provenance":[{"ts":"2026-06-30T00:34:01.708Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Selank for Tirzepatide\nSlug: selank-tirzepatide\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"dual_compound\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"selank\",\"name\":\"Selank\"},{\"id\":\"tirzepatide\",\"name\":\"Tirzepatide\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"selank\",\"name\":\"Selank\",\"section_title\":\"Why Selank might help you\",\"layer\":\"anxiety / neurochemistry\",\"steps\":[\"**What keeps failing:** Chronic stress chemistry, stimulant jitter, non-restorative arousal.\",\"**What Selank is studied to do:** Studied for anxiolytic pathways without classic benzodiazepine sedation.\",\"**Therefore for you:** If that layer is part of your problem, Selank is discussed because it targets repair (anxiety / neurochemistry) — not because it masks pain.\"],\"prose\":\"1. **What keeps failing:** Chronic stress chemistry, stimulant jitter, non-restorative arousal.\\n2. **What Selank is studied to do:** Studied for anxiolytic pathways without classic benzodiazepine sedation.\\n3. **Therefore for you:** If that layer is part of your problem, Selank is discussed because it targets repair (anxiety / neurochemistry) — not because it masks pain.\"},{\"peptide\":\"tirzepatide\",\"name\":\"Tirzepatide\",\"section_title\":\"Why Tirzepatide might help you\",\"layer\":\"metabolic load / body weight\",\"steps\":","response":"{\n  \"slug\": \"selank-tirzepatide\",\n  \"title\": \"Selank and Tirzepatide: Layered Evidence on Neurochemistry and Metabolic Pathways\",\n  \"body\": \"## What's breaking down\\n\\nNo single clinical condition is defined by the slug, so the layers come from the two compounds themselves. Tirzepatide targets metabolic load through GLP-1 and GIP receptor agonism, which produces weight loss but can coincide with reported psychiatric adverse events including anxiety in post-marketing data. Selank targets anxiety and neurochemistry pathways. When these two are considered together, the potential overlap is in the neurochemical stress layer that can accompany metabolic shifts.\\n\\n## Why Selank might help you\\n\\n1. **What keeps failing:** Chronic stress chemistry, non-restorative arousal states, or anxiety-like symptoms that may appear alongside metabolic therapies.\\n2. **What Selank is studied to do:** Human trials in Russia examined Selank in patients with generalized anxiety disorder and neurasthenia; it showed anxiolytic effects comparable to low-dose benzodiazepines without sedation, cognitive impairment, or dependence.\\n3. **Therefore for you:** If the anxiety or neurochemistry layer is part of your experience while using tirzepatide, Selank is discussed in the literature because it targets repair of that specific layer rather than broad suppression.\\n\\n## Why Tirzepatide might help you\\n\\n1. **What keeps failing:** Excess body weight creates mechanical and metabolic load on multiple systems.\\n2. **What Tirzepatide is studied to do:** Large human trials demonstrate substantial weight reduction via dual GLP-1/GIP agonism.\\n3. **Therefore for you:** If metabolic load contributes to overall strain, tirzepatide is discussed because it addresses that layer through documented weight-loss mechanisms.\\n\\n## How these fit together\\n\\nEach compound targets a different degeneration layer. Selank addresses anxiety and neurochemistry repair. Tirzepatide addresses metabolic load and body-weight ","tokens_in":13828,"tokens_out":2557,"cost":0,"prev":"genesis","hash":"8b4b2e51f299d0c076331498f5bd867a33f17c5156f42fb295026f8334eabf71"},{"ts":"2026-07-17T02:41:42.480Z","model":"owner","action":"voxel_divide","prompt":"","input":"selank-tirzepatide","response":"21 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"8b4b2e51f299d0c076331498f5bd867a33f17c5156f42fb295026f8334eabf71","hash":"d8cf2e2e3272b1f12ee9ca2696eb626ec8845121f478bbf386f3f52c1cbc1285"}],"energy":{"passes":2,"tokens_in":13828,"tokens_out":2557,"tokens_total":16385,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"d8cf2e2e3272b1f12ee9ca2696eb626ec8845121f478bbf386f3f52c1cbc1285"},"posted_at":"2026-06-29T21:33:08.354Z","created_at":"2026-06-29T21:33:08.354Z","updated_at":"2026-07-17T02:41:42.480Z","machine":{"shape":"article.machine/v1","slug":"selank-tirzepatide","kind":"article","read":{"human":"https://miscsubjects.com/a/selank-tirzepatide","json":"https://miscsubjects.com/api/articles/selank-tirzepatide","bundle":"https://miscsubjects.com/api/articles/selank-tirzepatide/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":3,"sources":3,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/selank-tirzepatide/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=selank-tirzepatide","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"selank-tirzepatide\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"selank-tirzepatide\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/selank-tirzepatide/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"selank-tirzepatide\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/selank-tirzepatide | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/selank-tirzepatide","json":"/api/articles/selank-tirzepatide","markdown":"/api/articles/selank-tirzepatide/bundle?format=markdown","skill":"/api/articles/selank-tirzepatide/skill","topology":"/api/articles/selank-tirzepatide/topology","versions":"/api/articles/selank-tirzepatide/revisions","invocations":"/api/articles/selank-tirzepatide/invocations"},"editorial_review":null,"editorial_audit":{"slug":"selank-tirzepatide","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"afc27c3a959f22e59a3dba9a475d16108655a779b7d830ce3259da89486ed268","object":{"object_type":"article-object","identity":{"id":"article:selank-tirzepatide","slug":"selank-tirzepatide","title":"Selank and Tirzepatide: Layered Evidence on Neurochemistry and Metabolic Pathways"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/selank-tirzepatide","role":"explain","audience":"human"},"skill":{"route":"/api/articles/selank-tirzepatide/skill","role":"direct behavior","audience":"model","content":"---\nname: selank-tirzepatide\ndescription: Apply the Selank and Tirzepatide: Layered Evidence on Neurochemistry and Metabolic Pathways article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# Selank and Tirzepatide: Layered Evidence on Neurochemistry and Metabolic Pathways\n\nThis Skill is the behavioral expression of [the canonical article](/a/selank-tirzepatide). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/selank-tirzepatide.\n- Read claims and relationships at /api/articles/selank-tirzepatide/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nWhat's breaking down No single clinical condition is defined by the slug, so the layers come from the two compounds themselves. Tirzepatide targets metabolic load through GLP-1 and GIP receptor agonism, which produces weight loss but can co\n\n## Representations\n\n- Human: /a/selank-tirzepatide\n- JSON: /api/articles/selank-tirzepatide\n- Relationships: /api/articles/selank-tirzepatide/topology\n- History: /api/articles/selank-tirzepatide/revisions\n"},"json":{"route":"/api/articles/selank-tirzepatide","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/selank-tirzepatide/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["peptide","matrix","selank","tirzepatide"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/selank-tirzepatide/invocations?status=success","failure_events":"/api/articles/selank-tirzepatide/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"selank-tirzepatide","title":"Selank and Tirzepatide: Layered Evidence on Neurochemistry and Metabolic Pathways","body":"## What's breaking down\n\nNo single clinical condition is defined by the slug, so the layers come from the two compounds themselves. Tirzepatide targets metabolic load through GLP-1 and GIP receptor agonism, which produces weight loss but can coincide with reported psychiatric adverse events including anxiety in post-marketing data. Selank targets anxiety and neurochemistry pathways. When these two are considered together, the potential overlap is in the neurochemical stress layer that can accompany metabolic shifts.\n\n## Why Selank might help you\n\n1. **What keeps failing:** Chronic stress chemistry, non-restorative arousal states, or anxiety-like symptoms that may appear alongside metabolic therapies.\n2. **What Selank is studied to do:** Human trials in Russia examined Selank in patients with generalized anxiety disorder and neurasthenia; it showed anxiolytic effects comparable to low-dose benzodiazepines without sedation, cognitive impairment, or dependence.\n3. **Therefore for you:** If the anxiety or neurochemistry layer is part of your experience while using tirzepatide, Selank is discussed in the literature because it targets repair of that specific layer rather than broad suppression.\n\n## Why Tirzepatide might help you\n\n1. **What keeps failing:** Excess body weight creates mechanical and metabolic load on multiple systems.\n2. **What Tirzepatide is studied to do:** Large human trials demonstrate substantial weight reduction via dual GLP-1/GIP agonism.\n3. **Therefore for you:** If metabolic load contributes to overall strain, tirzepatide is discussed because it addresses that layer through documented weight-loss mechanisms.\n\n## How these fit together\n\nEach compound targets a different degeneration layer. Selank addresses anxiety and neurochemistry repair. Tirzepatide addresses metabolic load and body-weight reduction. The stack maps separate pathways without repetition.\n\n## What the evidence actually shows\n\nHuman data for Selank consists of small Russian trials (n=30–70) comparing it to medazepam or phenazepam in generalized anxiety disorder; anxiolytic scores improved similarly but without typical benzodiazepine side effects (Zozulia 2008, Filatova 2017). These are the only published human efficacy studies; no large Western RCTs exist. Preclinical work shows Selank modulates GABA-A receptor subunits and cytokine expression.\n\nFor tirzepatide, SURMOUNT and SURPASS trials report robust weight loss and glycemic control in thousands of participants. FAERS analysis of GLP-1 agonists including tirzepatide found psychiatric adverse event reports at ~1.18% of total reports, with anxiety comprising 38.7% of those psychiatric events (Tobaiqy 2024). Case reports describe possible mood improvement in two patients (Psychiatrist.com 2025). No human trials examine Selank plus tirzepatide.\n\n## What scientists say\n\nRussian researchers conclude Selank produces anxiolytic effects comparable to classical benzodiazepines without sedation or dependence (PMC articles 4757669, 5322660). Western reviews note limited sample sizes and lack of independent replication. Tirzepatide researchers focus on metabolic endpoints; psychiatric signals are monitored through pharmacovigilance rather than dedicated neurochemistry trials.\n\n## What people say on Reddit\n\nA single thread in r/Nootropics describes one user combining Selank with semaglutide and reporting improved mood and reduced social anxiety. Broader tirzepatide discussions mention variable mood or anxiety-like sensations tied to GI effects or glucose shifts, with some users switching agents for better tolerability.\n\n## What people say on X\n\nPosts list both compounds among popular research peptides but contain no detailed user experiences of the combination. Mentions are primarily catalog-style references to cognitive or metabolic categories.\n\n## What we do not know\n\nNo direct interaction data, long-term human safety data for the pair, or controlled trials exist. Mechanisms by which tirzepatide might influence anxiety pathways remain speculative. Selank’s Western evidence base is small and untranslated in full.\n\n## Safety and limits\n\nSelank is approved in Russia but not elsewhere; human safety data are limited to weeks-to-months durations in small cohorts. Tirzepatide carries known GI and rare psychiatric reporting signals. Any combined use lacks regulatory evaluation. All statements are for informational purposes only.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/selank-tirzepatide/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"Small Russian human trials (n=30-70) showed Selank anxiolytic effects comparable to benzodiazepines without sedation or dependence in GAD patients.","section":"What the evidence actually shows","tier":"human","source_ids":["s1","s4"],"source_status":"sourced","why_material":"Establishes the only published human efficacy data for Selank.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:34:01.341Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"FAERS analysis found psychiatric adverse events in ~1.18% of GLP-1 agonist reports; anxiety was 38.7% of those events across semaglutide, liraglutide, and tirzepatide.","section":"What the evidence actually shows","tier":"human","source_ids":["s9"],"source_status":"sourced","why_material":"Quantifies real-world psychiatric signal for tirzepatide context.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:34:01.341Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"No human trials or published data examine Selank combined with tirzepatide.","section":"What we do not know","tier":"mechanistic","source_ids":[],"source_status":"unsourced","why_material":"Clarifies absence of direct evidence for the cross.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:34:01.341Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/18454096/","title":"Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank in the therapy of generalized anxiety disorders and neurasthenia","quote":"The increase of this parameter and stronger positive correlations with anxiety level were observed during the treatment with selank mostly in patients with GAD.","summary":"2008 Russian trial comparing Selank to medazepam in 62 GAD/neurasthenia patients.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:34:01.031Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"cf562137a860145e269aef72e8fef75cb6747cdb838abb96347254023a6931cf"},{"id":"s4","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5322660/","title":"Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety","quote":"Clinical studies have shown that the anxiolytic effect of Selank is comparable to the effect of low doses of the benzodiazepine tranquilizers","summary":"Reviews Selank clinical data versus benzodiazepines.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:34:01.031Z","link_status":"ok","quote_status":"verified","prev":"cf562137a860145e269aef72e8fef75cb6747cdb838abb96347254023a6931cf","hash":"1964c13fb8d7e87aed0d132f2f618aca127797616f859affff4ca82faac48115"},{"id":"s9","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10960895/","title":"Psychiatric adverse events associated with semaglutide, tirzepatide and liraglutide","quote":"Depression was the most commonly reported adverse event (n = 187; 50.3%), followed by anxiety (n = 144; 38.7%)","summary":"FAERS pharmacovigilance analysis of psychiatric reports for GLP-1 agonists.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:34:01.031Z","link_status":"ok","quote_status":"verified","prev":"1964c13fb8d7e87aed0d132f2f618aca127797616f859affff4ca82faac48115","hash":"31acc61b3b171b7d33edbc80a35828b3b8c7cada0ead6b21edc370582f7e4f60"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-30T00:34:01.708Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"Selank and Tirzepatide: Layered Evidence on Neurochemistry and Metabolic Pathways","register":"source_ledger","body":"## What's breaking down\n\nNo single clinical condition is defined by the slug, so the layers come from the two compounds themselves. Tirzepatide targets metabolic load through GLP-1 and GIP receptor agonism, which produces weight loss but can coincide with reported psychiatric adverse events including anxiety in post-marketing data. Selank targets anxiety and neurochemistry pathways. When these two are considered together, the potential overlap is in the neurochemical stress layer that can accompany metabolic shifts.\n\n## Why Selank might help you\n\n1. **What keeps failing:** Chronic stress chemistry, non-restorative arousal states, or anxiety-like symptoms that may appear alongside metabolic therapies.\n2. **What Selank is studied to do:** Human trials in Russia examined Selank in patients with generalized anxiety disorder and neurasthenia; it showed anxiolytic effects comparable to low-dose benzodiazepines without sedation, cognitive impairment, or dependence.\n3. **Therefore for you:** If the anxiety or neurochemistry layer is part of your experience while using tirzepatide, Selank is discussed in the literature because it targets repair of that specific layer rather than broad suppression.\n\n## Why Tirzepatide might help you\n\n1. **What keeps failing:** Excess body weight creates mechanical and metabolic load on multiple systems.\n2. **What Tirzepatide is studied to do:** Large human trials demonstrate substantial weight reduction via dual GLP-1/GIP agonism.\n3. **Therefore for you:** If metabolic load contributes to overall strain, tirzepatide is discussed because it addresses that layer through documented weight-loss mechanisms.\n\n## How these fit together\n\nEach compound targets a different degeneration layer. Selank addresses anxiety and neurochemistry repair. Tirzepatide addresses metabolic load and body-weight reduction. The stack maps separate pathways without repetition.\n\n## What the evidence actually shows\n\nHuman data for Selank consists of small Russian trials (n=30–70) comparing it to medazepam or phenazepam in generalized anxiety disorder; anxiolytic scores improved similarly but without typical benzodiazepine side effects (Zozulia 2008, Filatova 2017). These are the only published human efficacy studies; no large Western RCTs exist. Preclinical work shows Selank modulates GABA-A receptor subunits and cytokine expression.\n\nFor tirzepatide, SURMOUNT and SURPASS trials report robust weight loss and glycemic control in thousands of participants. FAERS analysis of GLP-1 agonists including tirzepatide found psychiatric adverse event reports at ~1.18% of total reports, with anxiety comprising 38.7% of those psychiatric events (Tobaiqy 2024). Case reports describe possible mood improvement in two patients (Psychiatrist.com 2025). No human trials examine Selank plus tirzepatide.\n\n## What scientists say\n\nRussian researchers conclude Selank produces anxiolytic effects comparable to classical benzodiazepines without sedation or dependence (PMC articles 4757669, 5322660). Western reviews note limited sample sizes and lack of independent replication. Tirzepatide researchers focus on metabolic endpoints; psychiatric signals are monitored through pharmacovigilance rather than dedicated neurochemistry trials.\n\n## What people say on Reddit\n\nA single thread in r/Nootropics describes one user combining Selank with semaglutide and reporting improved mood and reduced social anxiety. Broader tirzepatide discussions mention variable mood or anxiety-like sensations tied to GI effects or glucose shifts, with some users switching agents for better tolerability.\n\n## What people say on X\n\nPosts list both compounds among popular research peptides but contain no detailed user experiences of the combination. Mentions are primarily catalog-style references to cognitive or metabolic categories.\n\n## What we do not know\n\nNo direct interaction data, long-term human safety data for the pair, or controlled trials exist. Mechanisms by which tirzepatide might influence anxiety pathways remain speculative. Selank’s Western evidence base is small and untranslated in full.\n\n## Safety and limits\n\nSelank is approved in Russia but not elsewhere; human safety data are limited to weeks-to-months durations in small cohorts. Tirzepatide carries known GI and rare psychiatric reporting signals. Any combined use lacks regulatory evaluation. All statements are for informational purposes only.","claims":[{"id":"c1","text":"Small Russian human trials (n=30-70) showed Selank anxiolytic effects comparable to benzodiazepines without sedation or dependence in GAD patients.","section":"What the evidence actually shows","tier":"human","source_ids":["s1","s4"],"source_status":"sourced","why_material":"Establishes the only published human efficacy data for Selank.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:34:01.341Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"FAERS analysis found psychiatric adverse events in ~1.18% of GLP-1 agonist reports; anxiety was 38.7% of those events across semaglutide, liraglutide, and tirzepatide.","section":"What the evidence actually shows","tier":"human","source_ids":["s9"],"source_status":"sourced","why_material":"Quantifies real-world psychiatric signal for tirzepatide context.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:34:01.341Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"No human trials or published data examine Selank combined with tirzepatide.","section":"What we do not know","tier":"mechanistic","source_ids":[],"source_status":"unsourced","why_material":"Clarifies absence of direct evidence for the cross.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:34:01.341Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/18454096/","title":"Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank in the therapy of generalized anxiety disorders and neurasthenia","quote":"The increase of this parameter and stronger positive correlations with anxiety level were observed during the treatment with selank mostly in patients with GAD.","link_status":"ok","quote_status":"verified"},{"id":"s4","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5322660/","title":"Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety","quote":"Clinical studies have shown that the anxiolytic effect of Selank is comparable to the effect of low doses of the benzodiazepine tranquilizers","link_status":"ok","quote_status":"verified"},{"id":"s9","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10960895/","title":"Psychiatric adverse events associated with semaglutide, tirzepatide and liraglutide","quote":"Depression was the most commonly reported adverse event (n = 187; 50.3%), followed by anxiety (n = 144; 38.7%)","link_status":"ok","quote_status":"verified"}]},"rationale":"","tokens_in":13828,"tokens_out":2557,"cost":0.0236775,"prev_hash":"genesis","hash":"de42a6219b5b21a1cae4ea8286f8c9c82b5fbdcc80db896c94c7d9449150e501"}],"provenance":[{"ts":"2026-06-30T00:34:01.708Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Selank for Tirzepatide\nSlug: selank-tirzepatide\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"dual_compound\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"selank\",\"name\":\"Selank\"},{\"id\":\"tirzepatide\",\"name\":\"Tirzepatide\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"selank\",\"name\":\"Selank\",\"section_title\":\"Why Selank might help you\",\"layer\":\"anxiety / neurochemistry\",\"steps\":[\"**What keeps failing:** Chronic stress chemistry, stimulant jitter, non-restorative arousal.\",\"**What Selank is studied to do:** Studied for anxiolytic pathways without classic benzodiazepine sedation.\",\"**Therefore for you:** If that layer is part of your problem, Selank is discussed because it targets repair (anxiety / neurochemistry) — not because it masks pain.\"],\"prose\":\"1. **What keeps failing:** Chronic stress chemistry, stimulant jitter, non-restorative arousal.\\n2. **What Selank is studied to do:** Studied for anxiolytic pathways without classic benzodiazepine sedation.\\n3. **Therefore for you:** If that layer is part of your problem, Selank is discussed because it targets repair (anxiety / neurochemistry) — not because it masks pain.\"},{\"peptide\":\"tirzepatide\",\"name\":\"Tirzepatide\",\"section_title\":\"Why Tirzepatide might help you\",\"layer\":\"metabolic load / body weight\",\"steps\":","response":"{\n  \"slug\": \"selank-tirzepatide\",\n  \"title\": \"Selank and Tirzepatide: Layered Evidence on Neurochemistry and Metabolic Pathways\",\n  \"body\": \"## What's breaking down\\n\\nNo single clinical condition is defined by the slug, so the layers come from the two compounds themselves. Tirzepatide targets metabolic load through GLP-1 and GIP receptor agonism, which produces weight loss but can coincide with reported psychiatric adverse events including anxiety in post-marketing data. Selank targets anxiety and neurochemistry pathways. When these two are considered together, the potential overlap is in the neurochemical stress layer that can accompany metabolic shifts.\\n\\n## Why Selank might help you\\n\\n1. **What keeps failing:** Chronic stress chemistry, non-restorative arousal states, or anxiety-like symptoms that may appear alongside metabolic therapies.\\n2. **What Selank is studied to do:** Human trials in Russia examined Selank in patients with generalized anxiety disorder and neurasthenia; it showed anxiolytic effects comparable to low-dose benzodiazepines without sedation, cognitive impairment, or dependence.\\n3. **Therefore for you:** If the anxiety or neurochemistry layer is part of your experience while using tirzepatide, Selank is discussed in the literature because it targets repair of that specific layer rather than broad suppression.\\n\\n## Why Tirzepatide might help you\\n\\n1. **What keeps failing:** Excess body weight creates mechanical and metabolic load on multiple systems.\\n2. **What Tirzepatide is studied to do:** Large human trials demonstrate substantial weight reduction via dual GLP-1/GIP agonism.\\n3. **Therefore for you:** If metabolic load contributes to overall strain, tirzepatide is discussed because it addresses that layer through documented weight-loss mechanisms.\\n\\n## How these fit together\\n\\nEach compound targets a different degeneration layer. Selank addresses anxiety and neurochemistry repair. Tirzepatide addresses metabolic load and body-weight ","tokens_in":13828,"tokens_out":2557,"cost":0,"prev":"genesis","hash":"8b4b2e51f299d0c076331498f5bd867a33f17c5156f42fb295026f8334eabf71"},{"ts":"2026-07-17T02:41:42.480Z","model":"owner","action":"voxel_divide","prompt":"","input":"selank-tirzepatide","response":"21 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"8b4b2e51f299d0c076331498f5bd867a33f17c5156f42fb295026f8334eabf71","hash":"d8cf2e2e3272b1f12ee9ca2696eb626ec8845121f478bbf386f3f52c1cbc1285"}],"energy":{"passes":2,"tokens_in":13828,"tokens_out":2557,"tokens_total":16385,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"d8cf2e2e3272b1f12ee9ca2696eb626ec8845121f478bbf386f3f52c1cbc1285"},"posted_at":"2026-06-29T21:33:08.354Z","created_at":"2026-06-29T21:33:08.354Z","updated_at":"2026-07-17T02:41:42.480Z","machine":{"shape":"article.machine/v1","slug":"selank-tirzepatide","kind":"article","read":{"human":"https://miscsubjects.com/a/selank-tirzepatide","json":"https://miscsubjects.com/api/articles/selank-tirzepatide","bundle":"https://miscsubjects.com/api/articles/selank-tirzepatide/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":3,"sources":3,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/selank-tirzepatide/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=selank-tirzepatide","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"selank-tirzepatide\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"selank-tirzepatide\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/selank-tirzepatide/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"selank-tirzepatide\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/selank-tirzepatide | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/selank-tirzepatide","json":"/api/articles/selank-tirzepatide","markdown":"/api/articles/selank-tirzepatide/bundle?format=markdown","skill":"/api/articles/selank-tirzepatide/skill","topology":"/api/articles/selank-tirzepatide/topology","versions":"/api/articles/selank-tirzepatide/revisions","invocations":"/api/articles/selank-tirzepatide/invocations"},"editorial_review":null,"editorial_audit":{"slug":"selank-tirzepatide","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"afc27c3a959f22e59a3dba9a475d16108655a779b7d830ce3259da89486ed268"}}}